• SPX
  • 5969.34
  • 0.35 %
  • 20.6299
  • DJI
  • 44296.51
  • 0.97 %
  • 426.1602
  • N225
  • 38283.85
  • 0.68 %
  • 257.6797
  • FTSE
  • 8262.08
  • 1.38 %
  • 112.8101
  • IXIC
  • 19003.65
  • 0.16 %
  • 31.2305
Alvotech (ALVO) Stock Price, News & Analysis

Alvotech (ALVO) Stock Price, News & Analysis

Currency in USD Disclaimer

$12.02

-$0.42

(-3.38%)

Day's range
$11.82
Day's range
$12.3
50-day range
$9.15
Day's range
$13.3
  • Country: IS
  • ISIN: LU2458332611
52 wk range
$9
Day's range
$18


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -0.97
  • Piotroski Score 5.00
  • Grade Overweight
  • Symbol (ALVO)
  • Company Alvotech
  • Price $12.02
  • Changes Percentage (-3.38%)
  • Change -$0.42
  • Day Low $11.82
  • Day High $12.30
  • Year High $18.00

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/26/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $16.00
  • High Stock Price Target $22.00
  • Low Stock Price Target $10.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.08
  • Trailing P/E Ratio -6.75
  • Forward P/E Ratio -6.75
  • P/E Growth -6.75
  • Net Income $-551,731,000

Income Statement

Quarterly

Annual

Latest News of ALVO

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Alvotech Frequently Asked Questions

  • What were the earnings of ALVO in the last quarter?

    In the last quarter Alvotech earnings were on Thursday, August, 15th. The Alvotech maker reported $0.28 EPS for the quarter, beating analysts' consensus estimates of -$0.28 by $0.56.

  • What is the Alvotech stock price today?

    Today's price of Alvotech is $12.02 — it has decreased by -3.38% in the past 24 hours. Watch Alvotech stock price performance more closely on the chart.

  • Does Alvotech release reports?

    Yes, you can track Alvotech's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Alvotech stock forecast?

    Watch the Alvotech chart and read a more detailed Alvotech stock forecast to see what analysts suggest you do with its shares.

  • What is Alvotech stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Alvotech stock ticker.

  • How to buy Alvotech stocks?

    Like other stocks, ALVO shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Alvotech's EBITDA?

    Alvotech measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Alvotech’s financial statements.

  • What is the Alvotech's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -6.0341995319, which equates to approximately -603.42%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Alvotech stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Alvotech's financials relevant news, and technical analysis. Alvotech's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Alvotech stock currently indicates a “sell” signal. For more insights, review Alvotech’s technical analysis.

  • A revenue figure for Alvotech for its last quarter?

    Alvotech published it's last quarterly revenues at $102.89 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.